Structure of equine infectious anemia virus proteinase complexed with an inhibitor

被引:40
作者
Gustchina, A
Kervinen, J
Powell, DJ
Zdanov, A
Kay, J
Wlodawer, A
机构
[1] NCI, ABL BASIC RES PROGRAM, FREDERICK CANC RES & DEV CTR, MACROMOL STRUCT LAB, FREDERICK, MD 21702 USA
[2] UNIV WALES COLL CARDIFF, SCH MOL & MED BIOSCI, CARDIFF CF1 3US, S GLAM, WALES
关键词
AIDS; proteinase; retroviruses; specificity; structure;
D O I
10.1002/pro.5560050802
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Equine infectious anemia virus (EIAV), the causative agent of infectious anemia in horses, is a member of the lentiviral family. The virus-encoded proteinase (PR) processes viral polyproteins into functional molecules during replication and it also cleaves viral nucleocapsid protein during infection. The X-ray structure of a complex of the I54G mutant of EIAV PR with the inhibitor HBY-793 was solved at 1.8 Angstrom resolution and refined to a crystallographic R-factor of 0.136. The molecule is a dimer in which the monomers are related by a crystallographic twofold axis. Although both the enzyme and the inhibitor are symmetric, the interactions between the central part of the inhibitor and the active site aspartates are asymmetric, and the inhibitor and the two flaps are partially disordered. The overall fold of EIAV PR is very similar to that of other retroviral proteinases. However, a novel feature of the EIAV PR structure is the appearance of the second cr-helix in the monomer in a position predicted by the structural template for the family of aspartic proteinases. The parts of the EIAV PR with the highest resemblance to human immunodeficiency virus type 1 PR include the substrate-binding sites; thus, the differences in the specificity of both enzymes have to be explained by enzyme-ligand interactions at the periphery of the active site as well.
引用
收藏
页码:1453 / 1465
页数:13
相关论文
共 43 条
[1]   SUPERSECONDARY STRUCTURE OF ACID PROTEASES [J].
ANDREEVA, NS ;
GUSTCHINA, AE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1979, 87 (01) :32-42
[2]  
ANDREEVA NS, 1991, ADV EXP MED BIOL, V306, P559
[3]   STRUCTURAL BASIS OF DRUG-RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEINASE [J].
BALDWIN, ET ;
BHAT, TN ;
LIU, BS ;
PATTABIRAMAN, N ;
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (03) :244-249
[4]  
BRUNGER AT, 1992, XPLOR VERSION 3 1 SY
[5]  
CAMERON CE, 1995, ADV EXP MED BIOL, V253, P333
[6]  
CHEEVERS WP, 1985, REV INFECT DIS, V7, P83
[7]   FLAP OPENING IN HIV-1 PROTEASE SIMULATED BY ACTIVATED MOLECULAR-DYNAMICS [J].
COLLINS, JR ;
BURT, SK ;
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (04) :334-338
[8]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[9]   IN-VITRO RESISTANCE TO AN INHIBITOR OF HIV PROTEINASE (RO 31-8959) RELATIVE TO INHIBITORS OF REVERSE-TRANSCRIPTASE (AZT AND TIBO) [J].
CRAIG, JC ;
WHITTAKER, L ;
DUNCAN, IB ;
ROBERTS, NA .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (06) :335-339
[10]   ANALYSIS OF SUBSTRATE CLEAVAGE BY RECOMBINANT PROTEASE OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 REVEALS PREFERENCES AND SPECIFICITY OF BINDING [J].
DAENKE, S ;
SCHRAMM, HJ ;
BANGHAM, CRM .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :2233-2239